US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Ryman Healthcare Ltd (RYM) 銘柄情報

Ryman Healthcare Ltd (RYM)

1.90

0.045

(2.43%)

終了 6月12日 3:00PM

Ryman Healthcare Ltd (RYM) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

1.90

( 2.43% )

買値

1.905

売値

1.98

出来高

12,333

1.855 日の範囲 1.905

1.615 52 週間の範囲 2.64

時価総額

前日終値

1.855

始値

1.855

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 1,488,023

発行済株式数

1,014,541,794

配当利回り

PER

-13.31

1 株当たり利益 (EPS)

-0.17

歳入

854.47M

純利益

-171.35M

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the older people in New Zealand and Australia. The company’s villages provide apartments and townhouses, and assisted-living in serviced apartments, and care center, which offers rest ... Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the older people in New Zealand and Australia. The company’s villages provide apartments and townhouses, and assisted-living in serviced apartments, and care center, which offers rest homes, hospitals, specialist dementia care, and respite care services. Ryman Healthcare Limited was founded in 1984 and is based in Christchurch, New Zealand. 詳細を表示

セクター

Healthcare

業界

Healthcare Providers & Services

ウェブサイト

www.rymanhealthcare.co.nz

本社

Christchurch, New Zealand

設立

1984

Ryman Healthcare Ltd is listed in the Healthcare sector of the オーストラリア証券取引所 with ticker RYM. The last closing price for Ryman Healthcare was AUD1.86. Over the last year, Ryman Healthcare shares have traded in a share price range of AUD 1.615 to AUD 2.64.

Ryman Healthcare currently has 1,014,541,794 shares in issue. The market capitalisation of Ryman Healthcare is AUD1.93 billion. Ryman Healthcare has a price to earnings ratio (PE ratio) of -13.31.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.04	2.15053763441	1.86	1.905	1.845	3471	1.89430609	DE
4	0.04	2.15053763441	1.86	1.945	1.67	6736	1.85689186	DE
12	0.04	2.15053763441	1.86	1.945	1.615	7367	1.79473321	DE
26	-0.6	-24	2.5	2.64	1.615	10551	2.04078417	DE
52	-0.38	-16.6666666667	2.28	2.64	1.615	10960	2.18738039	DE
156	-0.38	-16.6666666667	2.28	2.64	1.615	10960	2.18738039	DE
260	-0.38	-16.6666666667	2.28	2.64	1.615	10960	2.18738039	DE

RYM - Frequently Asked Questions (FAQ)

What is the current Ryman Healthcare Ltd share price?

The current share price of Ryman Healthcare Ltd is AUD 1.90

How many Ryman Healthcare Ltd shares are in issue?

Ryman Healthcare Ltd has 1,014,541,794 shares in issue

What is the market cap of Ryman Healthcare Ltd?

The market capitalisation of Ryman Healthcare Ltd is AUD 1.93B

What is the 1 year trading range for Ryman Healthcare Ltd share price?

Ryman Healthcare Ltd has traded in the range of AUD 1.615 to AUD 2.64 during the past year

What is the PE ratio of Ryman Healthcare Ltd?

The price to earnings ratio of Ryman Healthcare Ltd is -13.31

What is the cash to sales ratio of Ryman Healthcare Ltd?

The cash to sales ratio of Ryman Healthcare Ltd is 2.67

What is the registered address of Ryman Healthcare Ltd?

The registered address for Ryman Healthcare Ltd is 92d Russley Road, Christchurch

What is the Ryman Healthcare Ltd website address?

The website address for Ryman Healthcare Ltd is www.rymanhealthcare.co.nz

Which industry sector does Ryman Healthcare Ltd operate in?

Ryman Healthcare Ltd operates in the Healthcare Providers & Services sector

CA Market News

CA Market News 8分前

Vertical Data and Quantum eMotion Partner to Bring Quantum Cybersecurity to AI Infrastructure DeploymentsJune 12, 2026 3:00 AM
ACCESS NewswireInitial Pilot Deployment Targeted for 2026 Across Vertical Data's GPU Cluster and Edge Data Center Pipeline

US Market News

US Market News 8分前

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year ResultsJune 12, 2026 3:00 AM
PR Newswire (US) class="legen

US Market News

US Market News 9分前

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year ResultsJune 12, 2026 3:00 AM
PR Newswire (US) class="legen

sharkey1

sharkey1 22分前

So we wait a year, or Accord scores the patent and Elite gets Tentative approval
then things might change .

iHub News

iHub News 23分前

SpaceX Secures $75 Billion Ahead of Historic Market DebutJune 12, 2026 2:45 AM
IH Market News SpaceX (NASDAQ:

sharkey1

sharkey1 30分前

THX, very confusing,
google says
None of these products have yet been approved by the FDA, and Elite therefore does not yet market any products. Elite Labs also engages in contract research ...Read more

no harm no foul
If they went to trial now, it would probly t

Libertas

Libertas 32分前

Thanks for sharing that, too bad most will write it off as nonsense.

🐻

IH Admin [Shelly]

IH Admin [Shelly] 32分前

Looks like your computer tried to login you in with your gmail account and it accidentally created a new alias.

Nightdaytrader

Nightdaytrader 35分前

Split T, next Friday is federal holiday and I believe markets are closed.

Nd9

God Bless America

God Bless America 50分前

Here I am. From 44 in 2008 to 62 now. So frustrated !

Split T

Split T 50分前

Just a friendly reminder that next Fiday June 19th is Quadruple. Witching Day, IMVHO we are going to see some crazy trading next week and due to the latest news I'm thinking we will be over $15.30 at close next Friday with volume in excess of 8 million shares according to my William Allen Getty.

God Bless America

God Bless America 57分前

No IPO for FNMA, FMCC. Just relist and do Second Public Offering.

God Bless America

God Bless America 59分前

No IPO for FNMA, FMCC. Just relist and do Second Public Offering

Tom turtles

Tom turtles 1時間前

US Market News

US Market News 1時間前

Caledonia Mining Corporation Plc: Utilisation of the Block Admission in Respect of ATM Sales AgreementJune 12, 2026 2:00 AM
ACCESS Newswire(NYSE American:CMCL)(AIM:CMCL)(VFEX:CMCL)SAINT HELIER, JE /

CA Market News

CA Market News 1時間前

Exercise of OptionsJune 12, 2026 2:00 AM
ACCESS NewswireTORONTO, ON / ACCESS Newswire / June 12, 2026 / Sintana Energy Inc. (TSXV:SEI)(AIM:SEI)(OTCQX:SEUSF) ("Sintana" o

US Market News

US Market News 1時間前

Caledonia Mining Corporation Plc: Director/PDMR Shareholding NotificationJune 12, 2026 2:05 AM
ACCESS Newswire(NYSE American:CMCL)(AIM:CMCL)(VFEX:CMCL)SAINT HELIER, JE / ACCES

Tom turtles

Tom turtles 1時間前

$1.62 after hours.....ya baby

space~farm

space~farm 1時間前

I can only imagine the deficiencies in their submission. This will be caught up in a never ending RFI.

jxyzobrien

jxyzobrien 2時間前

criminals run the country
so nothing will be done
lots of boot lickers

jxyzobrien

jxyzobrien 2時間前

bull market till qe dies
new fed chair will have some say next week
till change is clear its qe as usual.

rx7171

rx7171 2時間前

Negativity is primarily the funk we feel that we see extremely positive data that needs a longer and larger trial to get approval, delaying the approval for a minimum of three years.

Whether Anavex will even exist by then or be bought out is the unknown.

An investor’s b

JohnnyRotton

JohnnyRotton 2時間前

Most are stuck, this state allows unlimited shares if I remember right. They can dilute forever. Only a few will ever get out without a rs or buy back. They are making enough cash to do either if they choose. The stock cant achieve true value via rs because market cap is 1/10th actual value now. Tou

skitahoe

skitahoe 2時間前

During the past 5 or so years our market cap has shrunk from nearly $1 billion to the $307 million it is today. Dilution is less than doubled, yet the market cap is under about a third of what it was. The point is, LP has added much extra values, FlaskWorks, Advent, Roswell, etc. to what the compa

Ryman Healthcare

Sprock It Acquisitions

Atom Educacao E Editora ON

Magnetite Mines

KTEK Aerosystems

MA Money Residential Sec...

Lion Series 2020 1

Prodigy Gold NL

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。